Adverum Biotechnologies, Inc.
Symbool: ADVM
NASDAQ
10.43
USDMarktprijs vandaag
-0.9010
Koers/Winst Verhouding
0.0140
Koers/Winst Groei Verhouding
216.47M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Adverum Biotechnologies, Inc. (ADVM) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 519.35 | 96.5 | 185.6 | 305.2 | ||||||||||||
balance-sheet.row.short-term-investments | 160.24 | 21.5 | 117.2 | 271 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 5.7 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 24.04 | 6.2 | 5 | 6.2 | ||||||||||||
balance-sheet.row.total-current-assets | 543.38 | 102.8 | 190.6 | 317.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 328.46 | 67 | 113.9 | 119.1 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 9.78 | 2 | 2.5 | 3.3 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 5.16 | 1.2 | 1.4 | 0.3 | ||||||||||||
balance-sheet.row.total-non-current-assets | 343.4 | 70.2 | 117.8 | 122.6 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 886.79 | 173 | 308.4 | 439.7 | ||||||||||||
balance-sheet.row.account-payables | 8.37 | 1.9 | 2.2 | 1.4 | ||||||||||||
balance-sheet.row.short-term-debt | 72.39 | 10.4 | 13.2 | 1.9 | ||||||||||||
balance-sheet.row.tax-payables | 0.54 | 0.1 | 0.3 | 1.3 | ||||||||||||
balance-sheet.row.long-term-debt-total | 266.93 | 64.6 | 93.6 | 101.1 | ||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 33.49 | 12.5 | 16.8 | 2 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 266.93 | 64.6 | 94.6 | 102.2 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 328.92 | 64.6 | 106.8 | 103 | ||||||||||||
balance-sheet.row.total-liab | 411.69 | 89.5 | 126.9 | 123.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.04 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3510.69 | -919.8 | -802.6 | -648.1 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.43 | -0.5 | -1.5 | -0.7 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3988.17 | 1003.7 | 985.7 | 965 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 475.1 | 83.5 | 181.5 | 316.2 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 886.79 | 173 | 308.4 | 439.7 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 475.1 | 83.5 | 181.5 | 316.2 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 886.79 | - | - | - | ||||||||||||
Total Investments | 162.22 | 23.5 | 117.2 | 271 | ||||||||||||
balance-sheet.row.total-debt | 339.32 | 75 | 106.8 | 103 | ||||||||||||
balance-sheet.row.net-debt | -19.78 | 0 | 38.4 | 68.8 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -117.17 | -117.2 | -154.5 | -145.5 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 5.64 | 5.6 | 6.5 | 4.6 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.26 | 0.4 | 0 | 3.8 | ||||||||||||
cash-flows.row.stock-based-compensation | 17.57 | 17.6 | 20.1 | 25.2 | ||||||||||||
cash-flows.row.change-in-working-capital | -8.32 | -8.3 | 19.9 | 4.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | -0.37 | -0.4 | 0.8 | -1.6 | ||||||||||||
cash-flows.row.other-working-capital | -7.95 | -7.9 | 19 | 5.7 | ||||||||||||
cash-flows.row.other-non-cash-items | 18.55 | 10.6 | -0.1 | 0 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -90.98 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.81 | -0.8 | -11.8 | -15.1 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.purchases-of-investments | -36.72 | -36.7 | -104.4 | -407.5 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 134.4 | 134.4 | 257.9 | 501.3 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 96.88 | 96.9 | 141.7 | 78.7 | ||||||||||||
cash-flows.row.debt-repayment | -2.34 | 0 | -13.6 | -0.2 | ||||||||||||
cash-flows.row.common-stock-issued | 0.49 | 0.5 | 0 | 1.7 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 1.06 | -0.4 | 14.2 | 1 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -0.72 | 0.5 | 0.6 | 2.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 1.54 | 0.5 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 6.72 | 6.6 | 34.2 | -26.7 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 366.91 | 75 | 70.9 | 36.7 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 360.19 | 68.4 | 36.7 | 63.4 | ||||||||||||
cash-flows.row.operating-cash-flow | -90.98 | -91.3 | -108.1 | -107.8 | ||||||||||||
cash-flows.row.capital-expenditure | -0.81 | -0.8 | -11.8 | -15.1 | ||||||||||||
cash-flows.row.free-cash-flow | -91.79 | -92.1 | -119.9 | -123 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3.6 | 3.6 | 0 | 7.5 | ||||||||||||
income-statement-row.row.cost-of-revenue | 12.58 | 5.6 | 6.5 | 4.6 | ||||||||||||
income-statement-row.row.gross-profit | -8.98 | -2 | -6.5 | 2.9 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 77.48 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 49.91 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -1.01 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 5.75 | 5.7 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.operating-expenses | 126.38 | 121.7 | 157.1 | 153.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 127.39 | 127.4 | 157.1 | 153.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.interest-expense | -1.2 | 0 | -2.7 | 0 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -1.01 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 5.55 | 5.5 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 5.75 | 5.7 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.total-operating-expenses | 5.55 | 5.5 | 2.7 | 0.6 | ||||||||||||
income-statement-row.row.interest-expense | -1.2 | 0 | -2.7 | 0 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.64 | 5.6 | 6.5 | 4.6 | ||||||||||||
income-statement-row.row.ebitda-caps | -118.15 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -123.79 | -123.8 | -157.1 | -146.1 | ||||||||||||
income-statement-row.row.income-before-tax | -118.24 | -118.2 | -154.5 | -145.5 | ||||||||||||
income-statement-row.row.income-tax-expense | -1.08 | -1.1 | 0.1 | 0 | ||||||||||||
income-statement-row.row.net-income | -117.17 | -117.2 | -154.5 | -145.5 |
Vaak gestelde vragen
Wat is Adverum Biotechnologies, Inc. (ADVM) totale activa?
Adverum Biotechnologies, Inc. (ADVM) totale activa is 173010000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is -2.494.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -32.546.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -34.386.
Wat is Adverum Biotechnologies, Inc. (ADVM) nettowinst (netto-inkomen)?
De nettowinst is -117165000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 75036000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 121747000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 75000000.000.